ORR
Militia Long/Short Equity ETF
Set alert
- YTD
- +12.68%
- 1 year
- +21.77%
- Open
- 38.87
- Prev close
- 38.52
- Mkt cap
- 37.50M
- Vol
- 94.44K
- Avg vol
- 52.98K
- EPS
- 2.99
- P/E
- 12.88
- Div yield
- 0.00%
More statistics
- Low
- 38.41
- High
- 38.87
News
5 days ago gurufocus.com
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the n
6 days ago gurufocus.com
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced he
6 days ago gurufocus.com
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecif
6 days ago gurufocus.com
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancerPR Newswire
6 days ago gurufocus.com
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
IMDELLTRAÂ IN COMBINATION WITH IMFINZIÂ REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERPR NewswireTHOUSAND
1 week ago gurufocus.com
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026PR NewswireGUANGZHOU, C
1 week ago gurufocus.com
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve